Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results
A single injection of a microRNA therapeutic directed at a genetic target in the liver of hepatitis C patients produced a significant drop in viral load, according to interim results from an early-stage study announced Wednesday by Regulus Therapeutics ... - Wed, 22 Oct 2014 08:53

Promising hepatitis C drug = 100% gain
USA TODAY - Wed, 22 Oct 2014 14:33

Regulus soars on promising--but early--results for its hep C contender
FierceBiotech - Wed, 22 Oct 2014 06:46

Regulus Therapeutics Soars 90% On Hepatitis C Treatment News
Benzinga - Wed, 22 Oct 2014 07:41

Regulus surges on early hepatitis C drug data
Businessweek - Wed, 22 Oct 2014 10:48

Why Regulus Therapeutics Inc. Stock More Than Doubled
Nasdaq - Wed, 22 Oct 2014 13:15

Prisons balk at Sovaldi's $84000 cost for hepatitis C treatment
Nationwide, at least half a million inmates have chronic hepatitis C — and the net costs of treating them all with Sovaldi could exceed $30 billion, according to the new study in the Annals of Internal Medicine. The study concedes that funding Sovaldi ...
SFGate - Mon, 20 Oct 2014 17:18

For inmates, pricey hepatitis C drug could make financial sense
Stanford Medical Center Report - Mon, 20 Oct 2014 14:11

Officials Say Hepatitis C Drug Too Pricey To Give to All Calif. Inmates
California Healthline - Tue, 21 Oct 2014 07:02

Expensive Sovaldi drug for hepatitis C still most cost-effective choice for U ...
Tech Times - Wed, 22 Oct 2014 04:37

Email For inmates, pricey hepatitis C drug could make financial sense (blog) - Wed, 22 Oct 2014 04:05

Gilead's $1000-a-pill hepatitis C drug may make financial sense for prisons
San Francisco Business Times (blog) - Mon, 20 Oct 2014 14:11

Giving pricey hepatitis drug to prisoners may be financially wise
WHTC - Tue, 21 Oct 2014 14:11

Hepatitis C support group ran up €250000 in travel expenses
Around 1,000 women were infected with Hepatitis C after receiving the blood product which was negligently contaminated by the former Blood Transfusion Service Board. The virus attacks the liver and can cause death. In a statement, the HSE said it ...
Irish Independent - Wed, 22 Oct 2014 13:31

Alcohol, kennels, manicures - Hep C group spending revealed
Irish Times - Thu, 23 Oct 2014 01:25

HSE audit finds Hep C support group spent money on angel card readings and ... - Wed, 22 Oct 2014 10:11

HSE 'knew Hepatitis C group spent lavishly on booze and travel'
Irish Mirror - Thu, 23 Oct 2014 09:30

Positive Action director ran up €34k taxi bill
Irish Examiner - Wed, 22 Oct 2014 17:00

Positive Action: Irish taxpayers fund patient group's 'extravagant expenses'
BBC News - Thu, 23 Oct 2014 04:03

Prisoners with Hepatitis C Can't Get Expensive Drug that Actually Works
Around 17,000 California prison inmates have debilitating and deadly Hepatitis C, which until recently was extremely hard to treat. But a new wonder drug, Sovaldi, has hit the market and one pill a day for 12 weeks puts an end to most of the suffering.
AllGov - Fri, 24 Oct 2014 08:00

New Hepatitis C drug could be available shortly - Fri, 24 Oct 2014 04:28

Costly Hepatitis Drug For Prisoners Financially Viable?
Diabetes Insider - Fri, 24 Oct 2014 07:26

Senate Lawmaker Eyes Hearing on the Cost of Hepatitis C Treatments
Responding to the ongoing controversy over the prices for new hepatitis C treatments, U.S. Sen. Bernard Sanders (I-Vt.) will probably hold a hearing – possibly before the year ends – to examine how the cost is affecting the U.S. Department of Veterans ...
Wall Street Journal (blog) - Mon, 20 Oct 2014 08:20

Will High Price Hurt Gilead Sciences' New Hep-C Drug?
Barron's (blog) - Mon, 20 Oct 2014 11:51

What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock
Motley Fool - Mon, 20 Oct 2014 05:15

Gilead: Stage Set For Rally (GILD)
Seeking Alpha (registration) - Mon, 20 Oct 2014 05:33

The Price of Progress in Hepatitis C Management
The combination of sofosbuvir 400 mg once daily with pegylated interferon and ribavirin produced 90% SVRs at 12 weeks in treatment-naïve, genotype 1 patients with hepatitis C, and up to 96% in genotype 4 patients.8 The most common adverse events seen ... Managed Markets Network - Fri, 24 Oct 2014 05:45

Hepatitis C group paid €13000 for weekend of pampering
It said that giving therapies to women at weekend conferences took away the stigma of having to fill out forms divulging they had hepatitis C in other venues. The letter said that "even in Dublin, some members have issues accessing a qualified nurse ...
Irish Independent - Fri, 24 Oct 2014 18:41

Australia's rejection of costly new treatment sofosbuvir a 'death sentence for ...
Liver experts at a conference on the Gold Coast have been warned Australia is on the verge of a catastrophic death spiral from Hepatitis C. Dr Miriam Levy, the director of gastroenterology at Sydney's Liverpool Hospital, told the conference on Thursday ...
ABC Online - Thu, 23 Oct 2014 03:14

1  2  3  4  5  6  7  8    ->

We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014